TGFBR1 and hepatocellular carcinoma: In addition, previous studies demonstrated the promising antitumor effect of the TGFβR1 inhibitor galunisertib in combination with anti‐PD‐L1 in multiple tumors.[25, 26] However, their effect on HCC remains unclear.